ITGAM and neoplasm: Following the ex vivo treatment of tumor-infiltrated MDSCs with individual active compounds, the intensity of pStat3 in CD11b+/Ly6G+ MDSCs was also decreased, most profoundly by wedelolactone followed by apigenin and luteolin over the vehicle control (Fig. 6c).